| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/28/2002 | WO2002015933A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
| 02/28/2002 | WO2002015931A1 Immunologic method for the prevention of dental caries |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015918A2 Method and compositions for promoting osteogenesis |
| 02/28/2002 | WO2002015917A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 02/28/2002 | WO2002015916A1 Use of dihydroboswellic acids or hydrogenated extracts of boswellia for prophylactic and/or therapeutic treatment |
| 02/28/2002 | WO2002015908A1 Injections |
| 02/28/2002 | WO2002015904A1 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections |
| 02/28/2002 | WO2002015892A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015878A1 Aqueous suspension preparations |
| 02/28/2002 | WO2002015846A2 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/28/2002 | WO2002015809A2 Dental composition for hypersensitive teeth |
| 02/28/2002 | WO2002015722A2 Treatment of helicobacter with isothiocyanates |
| 02/28/2002 | WO2001087234A3 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers |
| 02/28/2002 | WO2001085779A3 Protein complexes and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001073029A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/28/2002 | WO2001070255A3 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 02/28/2002 | WO2001049309A3 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 02/28/2002 | WO2001045714A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001041776B1 Use of honey in medical dressings |
| 02/28/2002 | WO2001030812A3 Activation of hcv-specific t cells |
| 02/28/2002 | WO2001027254A3 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000073307A8 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 02/28/2002 | WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/28/2002 | WO2000040569A9 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 02/28/2002 | US20020026056 Substituted imidazoles having cytokine inhibitory activity |
| 02/28/2002 | US20020026051 Calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity |
| 02/28/2002 | US20020025983 Anticoagulant mixture; cardiovascular disordrs; premenstrual disorders; bone disorders |
| 02/28/2002 | US20020025970 Materials and methods for the treatment of gastroesophageal reflux disease |
| 02/28/2002 | US20020025966 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 02/28/2002 | US20020025936 Motilide compounds |
| 02/28/2002 | US20020025935 Antiinflammatory agents; autoimmune diseases; central nervous system disorders |
| 02/28/2002 | US20020025578 Intensified expression of nucleotide sequences in mammal; administer nucleic acids to mammal, transfect nucleotide sequence using voltage, monitor mammal for gene expression |
| 02/28/2002 | US20020025558 Human MAD proteins and uses thereof |
| 02/28/2002 | US20020025351 Therapeutic agent for treating ulcerative colitis |
| 02/28/2002 | US20020025348 Treatment for inflammatory bowel disease (IBD) and related conditions |
| 02/28/2002 | US20020025342 Novel administration form comprising an acid-labile active compound |
| 02/28/2002 | US20020025338 Bioavailable dosage form of isotrentinoin |
| 02/28/2002 | CA2674888A1 Anti-ige vaccines |
| 02/28/2002 | CA2674838A1 Anti-ige vaccines |
| 02/28/2002 | CA2456008A1 Stem cell differentiation |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/28/2002 | CA2420190A1 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2420154A1 Dental composition for hypersensitive teeth |
| 02/28/2002 | CA2420024A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | CA2419872A1 Identification of a human n-terminal acetyltransferase gene |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/28/2002 | CA2419580A1 Integrin receptor inhibitors |
| 02/28/2002 | CA2418730A1 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2418461A1 Method and compositions for promoting osteogenesis |
| 02/28/2002 | CA2417787A1 Lipid metabolism enzymes |
| 02/28/2002 | CA2416748A1 Improved specificity in treatment of diseases |
| 02/28/2002 | CA2415793A1 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections |
| 02/28/2002 | CA2356124A1 Anti-ige vaccines |
| 02/27/2002 | EP1181933A2 Use of growth hormone secretagogues for stimulating or increasing appetite |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181381A2 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181364A1 Lipid metabolism transcription factor |
| 02/27/2002 | EP1181354A1 Method for multiplying stem cells |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181315A1 LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
| 02/27/2002 | EP1181310A1 Chemokine receptor ccr3 antagonists |
| 02/27/2002 | EP1181305A1 Methods of modulating activity of prokaryotic ribosomes |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181290A1 Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| 02/27/2002 | EP1181289A1 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists |
| 02/27/2002 | EP1181286A1 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181285A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181284A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181278A1 Cyclic amine derivatives and their uses |
| 02/27/2002 | EP1181276A1 Morpholino-n-ethyl ester derivative of an indole spla-2 inhibitor |
| 02/27/2002 | EP1181275A1 Thio-oxindole derivatives |
| 02/27/2002 | EP1181055A2 Enzyme-activated anti-tumor prodrug compounds |
| 02/27/2002 | EP1181054A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| 02/27/2002 | EP1181047A2 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 02/27/2002 | EP1181037A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 02/27/2002 | EP1181017A1 Metalloprotease inhibitors |
| 02/27/2002 | EP1181014A1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD |
| 02/27/2002 | EP1181010A1 Pharmaceutical chewing gum formulations |
| 02/27/2002 | EP0939623B1 Oral delayed immediate release formulation and method of preparation therefor |
| 02/27/2002 | EP0825991B1 Diaryldiamine derivatives and their use as delta opioid (ant)-agonists |
| 02/27/2002 | EP0817770B1 Nonpeptides as tachykinin antagonists |
| 02/27/2002 | EP0687251B1 1,3-dihydroindol-2-one derivatives substituted in position 3 by a nitrogen group as vasopressin and/or ocytocine agonists and/or antagonists |
| 02/27/2002 | EP0587645B1 Benzo- and pyridopyran derivatives having anxiolytic and anti-convulsant activity |
| 02/27/2002 | CN1337964A Novel aralkyl amines of spirofuropyridines useful in therapy |
| 02/27/2002 | CN1337963A Pirazino (aza) indole derivatives |
| 02/27/2002 | CN1337962A Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| 02/27/2002 | CN1337961A Heteroaryl amidines, methyl amidiues and guanidines as protease inhibitors |
| 02/27/2002 | CN1337959A 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| 02/27/2002 | CN1337958A Compounds and methods for modulation of estroglen receptors |